Literature DB >> 15066244

Treatment of Venous Thromboembolism in Pregnancy.

Wee Shian Chan1.   

Abstract

Venous thromboembolism is a major preventable cause of maternal mortality in developed countries. Following objective diagnosis of deep vein thrombosis or pulmonary embolism, appropriate treatment with anticoagulation should be initiated. The therapeutic options in pregnancy are limited to the use of either unfractionated heparin or low molecular weight heparin. Oral anticoagulants, like warfarin, are relatively contraindicated for use during pregnancy for the treatment of venous thromboembolism because they freely cross the placenta and can be associated with adverse fetal effects. The appropriate length of treatment for acute venous thromboembolic disease diagnosed during pregnancy should be at least 3 months and possibly up till 6 weeks after delivery.

Entities:  

Year:  2004        PMID: 15066244     DOI: 10.1007/s11936-004-0043-2

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  57 in total

1.  The cumulative incidence of venous thromboembolism during pregnancy and puerperium--an 11 year Danish population-based study of 63,300 pregnancies.

Authors:  B S Andersen; F H Steffensen; H T Sørensen; G L Nielsen; J Olsen
Journal:  Acta Obstet Gynecol Scand       Date:  1998-02       Impact factor: 3.636

2.  Venous circulation in the maternal lower limb: a Doppler study with the Valsalva maneuver.

Authors:  J Palmgren; P Kirkinen
Journal:  Ultrasound Obstet Gynecol       Date:  1996-08       Impact factor: 7.299

3.  Functional and immunologic protein S levels are decreased during pregnancy.

Authors:  P C Comp; G R Thurnau; J Welsh; C T Esmon
Journal:  Blood       Date:  1986-10       Impact factor: 22.113

4.  The blood coagulation and fibrinolytic systems in the newborn and the mother at birth.

Authors:  J Bonnar; G P McNicol; A S Douglas
Journal:  J Obstet Gynaecol Br Commonw       Date:  1971-04

Review 5.  Safety of low-molecular-weight heparin in pregnancy: a systematic review.

Authors:  B J Sanson; A W Lensing; M H Prins; J S Ginsberg; Z S Barkagan; E Lavenne-Pardonge; B Brenner; M Dulitzky; J D Nielsen; Z Boda; S Turi; M R Mac Gillavry; K Hamulyák; I M Theunissen; B J Hunt; H R Büller
Journal:  Thromb Haemost       Date:  1999-05       Impact factor: 5.249

6.  Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk.

Authors:  C Nelson-Piercy; E A Letsky; M de Swiet
Journal:  Am J Obstet Gynecol       Date:  1997-05       Impact factor: 8.661

Review 7.  Low molecular weight heparin use during pregnancy: issues of safety and practicality.

Authors:  W S Chan; J G Ray
Journal:  Obstet Gynecol Surv       Date:  1999-10       Impact factor: 2.347

8.  Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis.

Authors:  A Leizorovicz; G Simonneau; H Decousus; J P Boissel
Journal:  BMJ       Date:  1994-07-30

9.  Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin.

Authors:  T C Dahlman
Journal:  Am J Obstet Gynecol       Date:  1993-04       Impact factor: 8.661

10.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.